Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on July 5, 2017. The filing addresses executive leadership transitions and compensatory arrangements effective July 3, 2017, and July 6, 2017.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes
- Executive Appointment: William McVicar, Ph.D., assumed the role of interim President and Chief Executive Officer on July 3, 2017, replacing Christoph Westphal, M.D., Ph.D.
- Compensation Adjustment (McVicar): An amendment to Dr. McVicar's employment agreement provides an additional $5,000 monthly stipend for his interim role. Additionally, he was granted an option to purchase 50,000 shares of Common Stock at the closing price on the grant date, vesting monthly over four years.
- Compensation Adjustment (Westphal): The Board approved a monthly retainer of $30,000 for Dr. Westphal for his service as Chairman of the Board during the interim CEO period.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingency noted is the interim nature of Dr. McVicar's CEO role and the specific vesting schedule of his stock options.
Investor Verification Checklist
- Verify the exact closing price of Flex Pharma's Common Stock on the grant date to determine the exercise price of Dr. McVicar's 50,000 share option.
- Confirm the duration of Dr. McVicar's interim CEO tenure to calculate the total potential stipend payout.
- Review the full text of the Amendment to Executive Employment Agreement (Exhibit 10.1) for additional terms not summarized in the 8-K.
- Clarify the company identity, as the input metadata referenced "Decoy Therapeutics Inc." while the filing text explicitly identifies "Flex Pharma, Inc."